OR2D2

Across TCGA pan-cancer cohorts, OR2D2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated OR2D2 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher OR2D2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR2D2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, ESCA, and PRAD are the cancer types where OR2D2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.228	0.729	.014	15	view →
ESCA	DFS	Median	All	0.075	0.533	<.001	12	view →
PRAD	OS	Median	All	0.800	0.990	<.001	6	view →
UCEC	DFS	Median	II,III,IV	1.000	0.488	.047	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

OR2D2–STAD (OS)

Open the STAD breakdown →